Dalbavancin
It is also used to treat Staphylococcus aureus bacteremia once identified on blood culture and S. aureus bone or joint infections.[2][1] In a randomized trial involving 200 patients with complicated S. aureus bacteremia, 2 doses of intravenous dalbavancin were noninferior to 4 to 8 weeks of other
Authors
- Anthony D. Bai (ORCID: https://orcid.org/0000-0003-0448-9934)
- Kiarah Shchepanik
- Isabella R. Stevenson
Institutions
- Kingston Health Sciences Centre (CA)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2026-03-15
- DOI
- https://doi.org/10.1503/cmaj.251756
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00